Discontinue treatment in patients who develop VTE. Not recommended in patient w/ history of VTE. Not to be re-administered if on pending exam there is sudden partial or complete loss of vision or sudden onset of proptosis, diplopia or migraine; if exam reveals papilloedema or retinal vascular lesions. Fluid retention; decreased glucose tolerance; Cushingoid symptoms. May decrease ACTH & hydrocortisone blood levels; endocrine biomarker levels including plasma/urinary steroids (eg, cortisol, estrogen, pregnanediol, progesterone, testosterone); plasma/urinary gonadotrophins (eg, LH & FSH; sex hormone-binding-globulin. Increased risk of developing osteoporosis in pre-menopausal woman. Decreased bone mineral density during 1st 2 yr of treatment. May cause partial adrenal insufficiency during metapyrone testing when used in oncology indications. Investigate unexpected vag bleeding during therapy. Carefully monitor patients w/ treatment history for clinical depression. Patient w/ pre-existing medical condition adversely affected by fluid retention. Observe diabetic patients during therapy. Evaluate bone mineral density in patients on long-term therapy. Ensure adequate Ca & vit D intake. May affect ability to drive & use machines. Severe liver insufficiency.
Sign Out
